[Diffuse large B-cell lymphoma: standard treatment and research questions]

Area of Science:

• Hematology
• Oncology
• Clinical Practice Guidelines

Background:

• The Japanese Society of Hematology revised its practical guidelines for hematological malignancies in 2018.
• Diffuse large B-cell lymphoma (DLBCL) is a significant hematological malignancy.
• R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard treatment for DLBCL since the early 2000s.

Purpose of the Study:

• To review the current evidence regarding treatments for diffuse large B-cell lymphoma (DLBCL).
• To identify and discuss the challenges and limitations associated with existing DLBCL treatment protocols.
• To explore unanswered research questions stemming from decades of DLBCL treatment research.

Main Methods:

• Literature review of clinical trials and guidelines related to DLBCL treatment.
• Analysis of the efficacy and limitations of the R-CHOP regimen.
• Synthesis of evidence on attempts to improve upon standard DLBCL therapy.

Main Results:

• R-CHOP continues to be the recommended standard treatment for DLBCL, consistent with previous guidelines.
• Despite numerous clinical trials, attempts to significantly improve survival beyond R-CHOP have largely been unsuccessful.
• The established efficacy of R-CHOP highlights the need for further research into novel therapeutic strategies.

Conclusions:

• R-CHOP remains the cornerstone of DLBCL treatment, demonstrating sustained effectiveness.
• The lack of significant advancements beyond R-CHOP underscores the complexity of treating DLBCL.
• Further research is essential to address persistent challenges and improve outcomes for DLBCL patients.